Johnson & Johnson has signed a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly owned subsidiary of Abbott Laboratories, for $4.32bn in cash.

AMO posted sales of $1.1bn in 2015.

The acquisition will include ophthalmic products in three business segments including cataract surgery, laser refractive surgery and consumer eye health.

“With this acquisition we will enter cataract surgery, one of the most commonly performed surgeries and the number one cause of preventable blindness.”

Johnson & Johnson vision care companies group chairman Ashley McEvoy said: “Eye health is one of the largest, fastest growing and most underserved segments in health care today.

“With the acquisition of Abbott Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled with our world-leading ACUVUE contact lens business, we will become a more broad-based leader in vision care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Importantly, with this acquisition we will enter cataract surgery, one of the most commonly performed surgeries and the number one cause of preventable blindness.”

AMO is an important player in ophthalmic surgery and is known for intraocular lenses used in cataract surgery.

According to the World Health Organization estimates, approximately 20 million people are blind from age-related cataracts and there are at least 100 million eyes with compromised visual acuity caused by cataracts. These numbers are rising due to population growth and increasing life expectancy.

Besides the cataract business, AMO has advanced laser vision (LASIK) technologies designed to enhance surgeon productivity and correct near sightedness, far sightedness and astigmatism.

The deal also includes AMO’s consumer eye health products such as over-the-counter drops for dry eyes, as well as multipurpose solutions and hydrogen peroxide cleaning systems for patients wearing contact lenses.

The transaction is expected to complete in the first quarter of 2017 following regulatory approvals.